Blood-based biomarkers (BBMs) hold promise for a fast, convenient, and simple means to accurately diagnose Alzheimer's Disease.

The European Medicines Agency (EMA) began mandatory use of the new Clinical Trials Information System (CTIS) as of Tuesday, Jan. 31, 2023.

Starting treatment immediately after a cancer diagnosis seems logical; however, doing so before having biomarker testing may be inadvisable.